Atterx Biotherapeutics

Atterx Biotherapeutics, founded in 2001 and previously known as Conjugon, is a clinical-stage specialty pharmaceutical company addressing the critical market of multi-drug resistant bacterial infections. The company operates from Traverse City, Michigan, after relocating its headquarters from Madison, Wisconsin. The move was driven by CEO James V. Millar, who joined initially as a consultant and board member before taking the helm to guide the company through crucial clinical trial stages and capital fundraising. His background includes over 20 years in finance and business development, having advised on transactions valued at over $1 billion.

Atterx is focused on developing novel therapeutics for a healthcare sector grappling with rising antibiotic resistance. Its business model centers on the research, development, and eventual commercialization of proprietary treatments that have the potential to significantly reduce reliance on conventional antibiotics. The company targets healthcare providers and hospitals, aiming to prevent and treat severe infections. Atterx has secured significant funding to advance its pipeline, raising a total of $14.1 million over 11 rounds from investors including Boomerang Catapult, Wisconsin Investment Partners, and Michigan Rise.

The company's product pipeline features two primary candidates. The first, C-1205, employs bacterial interference technology to prevent catheter-associated urinary tract infections (CAUTIs), which are a major source of hospital-acquired infections. Atterx has an Investigational New Drug (IND) application on file with the FDA for C-1205 and is preparing to enter a combined Phase I/II clinical trial. The second core technology utilizes bacterial conjugation to treat infections. Its product candidate, GN-4474, is designed to combat Gram-negative bacteria and has demonstrated effectiveness in animal models, with an IND filing anticipated.

Keywords: Atterx Biotherapeutics, multi-drug resistant bacteria, antibiotic resistance, bacterial interference, bacterial conjugation, catheter-associated urinary tract infections, CAUTI, C-1205, GN-4474, biotherapeutics, clinical-stage pharmaceutical, antimicrobial, gram-negative bacteria, James V. Millar, Steven R. Watt, Traverse City biotech, infectious disease treatment, hospital-acquired infections, IND, FDA Fast Track